News

Filter

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

08-09-2014

UK inhalation drug delivery specialist Skyepharma today announced that data from a randomized, multicenter,…

FlutiformGermanyMundipharmaPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySkyepharmaUK

Skyepharma launches Flutiform in France for asthma

10-02-2014

UK drug delivery specialist Skyepharma has received regulatory approval and agreement on pricing reimbursement…

FlutiformFranceMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Flutiform trial for COPD initiated in Europe

Flutiform trial for COPD initiated in Europe

19-09-2013

UK drug delivery specialist Skyepharma (LSE: SKP) and privately-held Swiss drugmaker Mundipharma, which…

FlutiformMundipharmaPharmaceuticalResearchRespiratory and PulmonarySkyepharma

SkyePharma/Mundipharma's Flutiform launched in Germany

23-09-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform,…

EuropeFlutiformMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Flutiform receives UK regulatory approval; solid financials from SkyePharma

24-08-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) yesterday announced that the UK the Medicines…

FinancialFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

European approval for Mundipharma/SkyePharma's asthma drug Flutiform

04-07-2012

After some delays, the European Commission has now adopted a legally binding decision in favor of granting…

EuropeFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

COMPANY SPOTLIGHT

Menarini

Back to top